View Financial HealthNovozymes 配当と自社株買い配当金 基準チェック /46Novozymes配当を支払う会社であり、現在の利回りは1.68%で、収益によって十分にカバーされています。主要情報1.7%配当利回り0.1%バイバック利回り総株主利回り1.8%将来の配当利回り2.1%配当成長6.4%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向68%最近の配当と自社株買いの更新お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.すべての更新を表示Recent updatesReported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmarkお知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: NZM2の配当金支払いは、過去10年間 変動性 が高かった。増加する配当: NZM2の配当金は過去10年間にわたって増加しています。配当利回り対市場Novozymes 配当利回り対市場NZM2 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NZM2)1.7%市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Chemicals)3.7%アナリスト予想 (NZM2) (最長3年)2.1%注目すべき配当: NZM2の配当金 ( 1.68% ) はGerman市場の配当金支払者の下位 25% ( 1.54% ) よりも高くなっています。高配当: NZM2の配当金 ( 1.68% ) はGerman市場の配当金支払者の上位 25% ( 4.55% ) と比較すると低いです。株主への利益配当収益カバレッジ: NZM2の配当金は、合理的な 配当性向 ( 68.1% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: NZM2は合理的な 現金配当性向 ( 52.4% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 08:54終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Novozymes A/S 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28 アナリスト機関Alexander SloaneBarclaysCezara LozneanuBarclaysSebastian SatzBarclays25 その他のアナリストを表示
お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).
Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
Reported Earnings • May 06First quarter 2026 earnings released: EPS: €0.43 (vs €0.40 in 1Q 2025)First quarter 2026 results: EPS: €0.43 (up from €0.40 in 1Q 2025). Revenue: €1.12b (up 3.9% from 1Q 2025). Net income: €199.1m (up 7.0% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.
お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
Upcoming Dividend • Mar 17Upcoming dividend of kr.4.25 per shareEligible shareholders must have bought the stock before 24 March 2026. Payment date: 26 March 2026. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (4.0%).
Reported Earnings • Mar 03Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)Full year 2025 results: EPS: €1.25 (up from €1.10 in FY 2024). Revenue: €4.16b (up 8.5% from FY 2024). Net income: €583.6m (up 91% from FY 2024). Profit margin: 14% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
Declared Dividend • Feb 28Dividend of kr.4.25 announcedShareholders will receive a dividend of kr.4.25. Ex-date: 24th March 2026 Payment date: 26th March 2026 Dividend yield will be 9.1%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark
お知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
Buy Or Sell Opportunity • Jan 22Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €55.22. The fair value is estimated to be €45.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.3% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)Third quarter 2025 results: EPS: €0.29 (down from €0.33 in 3Q 2024). Revenue: €1.06b (up 4.4% from 3Q 2024). Net income: €138.0m (down 11% from 3Q 2024). Profit margin: 13% (down from 15% in 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany.
お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
Board Change • Sep 11High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.